Abby L Ricket1, David W Stewart2, Robert C Wood3, Lyndsey Cornett4, Brian Odle4, David Cluck4, Jessica Freshour4, Hadi El-Bazouni4. 1. Manchester University, Fort Wayne, IN, USA. 2. East Tennessee State University, Johnson City, TN, USA stewardw@etsu.edu. 3. East Tennessee State University, Johnson City, TN, USA James H. Quillen Veterans' Affairs Medical Center, Mountain Home, TN, USA. 4. East Tennessee State University, Johnson City, TN, USA.
Abstract
BACKGROUND: The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg daily with commonly used doses of enoxaparin and demonstrated similar rates of VTE and bleeding. OBJECTIVE: To evaluate bleeding events between patients who received enoxaparin or rivaroxaban for prevention of venous thromboembolism (VTE) following total hip arthroplasty (THA) or total knee arthroplasty (TKA). METHODS: Retrospective cohort that compared patients undergoing THA and TKA who received enoxaparin (enoxaparin) with those who received rivaroxaban (rivaroxaban) and also with those who received enoxaparin in the RECORD 1 to 4 trials (enoxaparin RECORD). The primary outcome was any postoperative bleeding, defined as a composite of major and clinically relevant nonmajor bleeding based on the definitions in the RECORD 1 to 4 trials. RESULTS: There was a lower rate of any postoperative bleeding (2.2% vs 6.8%, P = 0.004) in patients who received enoxaparin compared with rivaroxaban, and bleeding rates between the enoxaparin group and the enoxaparin RECORD groups were similar (2.2% vs 2.5%, P = 0.085). Major bleeding in the enoxaparin group (0.2%) was not significantly different from that in the rivaroxaban group (1.4%, P = 0.12) or the RECORD group (0.2%, P = 0.93). Clinically relevant nonmajor bleeding was also lower in the enoxaparin group compared with the rivaroxaban group (2.0% vs 5.5%, P = 0.012). CONCLUSIONS: The use of enoxaparin for VTE prophylaxis following THA and TKA was associated with a lower rate of the primary outcome (any postoperative bleeding) compared with the use of rivaroxaban in a similar cohort of patients.
BACKGROUND: The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg daily with commonly used doses of enoxaparin and demonstrated similar rates of VTE and bleeding. OBJECTIVE: To evaluate bleeding events between patients who received enoxaparin or rivaroxaban for prevention of venous thromboembolism (VTE) following total hip arthroplasty (THA) or total knee arthroplasty (TKA). METHODS: Retrospective cohort that compared patients undergoing THA and TKA who received enoxaparin (enoxaparin) with those who received rivaroxaban (rivaroxaban) and also with those who received enoxaparin in the RECORD 1 to 4 trials (enoxaparin RECORD). The primary outcome was any postoperative bleeding, defined as a composite of major and clinically relevant nonmajor bleeding based on the definitions in the RECORD 1 to 4 trials. RESULTS: There was a lower rate of any postoperative bleeding (2.2% vs 6.8%, P = 0.004) in patients who received enoxaparin compared with rivaroxaban, and bleeding rates between the enoxaparin group and the enoxaparin RECORD groups were similar (2.2% vs 2.5%, P = 0.085). Major bleeding in the enoxaparin group (0.2%) was not significantly different from that in the rivaroxaban group (1.4%, P = 0.12) or the RECORD group (0.2%, P = 0.93). Clinically relevant nonmajor bleeding was also lower in the enoxaparin group compared with the rivaroxaban group (2.0% vs 5.5%, P = 0.012). CONCLUSIONS: The use of enoxaparin for VTE prophylaxis following THA and TKA was associated with a lower rate of the primary outcome (any postoperative bleeding) compared with the use of rivaroxaban in a similar cohort of patients.
Authors: Troy Li; Mica Curtin-Bowen; Avery Pullman; Stuart Lipsitz; Ania Syrowatka; Michael Sainlaire; Tien Thai; Alexandra Businger; Aileen Davis; Jay R Lieberman; Bonnie Blanchfield; David W Bates; Patricia C Dykes Journal: AMIA Annu Symp Proc Date: 2022-02-21
Authors: Zengfa Deng; Puyi Sheng; Dongliang Xu; Ming Fu; Aishan He; Weiming Liao; Yan Kang Journal: Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi Date: 2020-12-15
Authors: Chi Zhang; Bo Xu; Guanzhao Liang; Xianshang Zeng; Chen Yang; Fan Zhang; Zi Wan; Weiguang Yu; Deng Chen; Zhe Ge; Xinchao Zhang Journal: J Int Med Res Date: 2018-03-21 Impact factor: 1.671
Authors: Yong Tae Kim; Min Wook Kang; Joon Kyu Lee; Young Min Lee; Joong Il Kim Journal: BMC Musculoskelet Disord Date: 2018-07-18 Impact factor: 2.362
Authors: Daniel C Santana; Matthew J Hadad; Ahmed Emara; Alison K Klika; Wael Barsoum; Robert M Molloy; Viktor E Krebs; Michael R Bloomfield; Nicolas S Piuzzi Journal: Medicina (Kaunas) Date: 2021-02-23 Impact factor: 2.430